A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report

Gozzetti, Alessandro; Cerase, Alfonso; Crupi, Rosaria; Raspadori, Donatella; Defina, Marzia; Bocchia, Monica; Lauria, Francesco

doi:10.1016/j.leukres.2011.06.034

Cited by 5 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,15,16,18,20,[22][23][24] Indeed, the great majority of CNS-MM described in the literature were reported either before the era of flow cytometry or before the consolidated use of such a method in the diagnostic approach to MM and related diseases.…”

Section: Discussionmentioning

confidence: 99%

“…8,15,16,18,20,[22][23][24] Non-homogeneous results were available, since cytogenetics was not reported in 4 cases and data about CD56 expression were not reported in 3 cases. Significant neurologic symptoms were described in all cases but one, but in 2 cases MRI was negative.…”

Section: Review Of Cases Studied By Flow Cytometrymentioning

confidence: 99%

“…Monitoring of CSF showed plasma cell clearance in some cases, either after intrathecal therapy 15,16,18,20 or by administering drugs capable of crossing the blood-brain barrier, such as lenalidomide 23 and pomalidomide. 24 Radiotherapy as adjuvant treatment was given in two cases, 15,22 but it not was possible to established its role in patients' outcome.…”

Section: Review Of Cases Studied By Flow Cytometrymentioning

confidence: 99%

“…We found only eight cases of CNS-MM diagnosed by means of flow cytometry. 8,15,16,18,20,[22][23][24] Thus, in the current paper we report both our experience and a review of previous cases investigated by flow cytometric methods.…”

Section: Introductionmentioning

confidence: 98%

“…We found that a total number of 187 cases had been reported until 2012. [3][4][5][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] The same case was described in two different instances. 19,23 Therefore, we reviewed review articles and single case reports in order to obtain more information about patients characteristics, the method used to detect plasma cells in the CSF and plasma cell phenotype.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Myelomatous Meningitis Evaluated by Multiparameter Flow Cytometry : Report of a Case and Review of the Literature

Marini

Carulli

Lari

et al. 2014

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Central nervous system (CNS) involvement in multiple myeloma (MM) is uncommon. Among its possible presentations, leptomeningeal involvement of MM, also termed central nervous system myelomatosis (CNS-MM) is rare and is characterized by the presence of neoplastic plasma cells in the cerebrospinal fluid (CSF). So far, 187 cases of CNS-MM have been reported : the great majority of them were diagnosed by cytological assays and flow cytometry was used in only eight cases. We describe a case of CNS-MM in a 62-year-old woman, previously treated with chemotherapy (VTD) and autologous peripheral blood hematopoietic stem cell transplantation for stage IIIB IgG-l MM. After achieving a very good partial response, the patient showed progression of disease, with an extramedullary localization. During administration of second-line therapy, the patient showed severe neurological symptoms. MRI resulted negative. Diagnosis of CNS-MM was made by multiparameter flow cytometry, which showed the presence of CD56 + plasma cells in a CSF sample, in the absence of plasma cell leukemia. In this paper we also present a review of the eight previous cases of CNS-MM diagnosed by flow cytometry. We found that the application of flow cytometry in cases of MM with neurological symptoms allows a rapid diagnosis of CNS-MM and provides useful information about plasma cell phenotype (including CD56 expression). Some cases of CNS-MM are characterized by normal MRI. In addition, some evidences deriving from the review of literature suggest that CSF monitoring by flow cytometry in such cases might be used to evaluate the efficacy of drugs capable of crossing the blood-brain barrier. 〔J Clin Exp Hematop 54 (2) : 129-136, 2014〕

show abstract